Wird diese Nachricht nicht richtig dargestellt, klicken Sie bitte hier.

What´s up at IZB

Dear Mister/Miss Titel ,

We are pleased to send you our latest IZB newsletter with our new image film. And of course there is lots of news from our start-ups. We have also produced a very informative new video about CatalYm. Don't miss it!

As part of BIO-Europe, we had the opportunity to present the IZB to over 90 international guests. A great success. The Peutinger Collegium also visited us and was impressed by the innovative strength of the location.

With best regards

Yours

Dr. Peter Hanns Zobel
Managing Director IZB

IZB News

IZB:

Christmas Greetings

We wish you and your loved ones a wonderful festive season and a happy und successful 2024.

Watch video

IZB:

New image film of the IZB

The innovation and start-up center for biotechnology in Planegg-Martinsried and Freising-Weihenstephan has developed into a leading biotechnology center. 40 biotech companies and five life science companies with over 700 employees are currently located on 26,000 square meters

EpiQmax:

MoleQlar receives seed funding from Rheingau Founders and acquires Munich-based epigenetics specialist EpiQMAx
NOVEMBER 9, 2023

One of the leading companies for longevity nutritional supplements and health tests, combines high technical expertise with forward-looking approaches to keep pace with rapid progress.

CatalYm:

Neutralizing GDF-15: Development of a new class of anti-cancer immunotherapy

CatalYm combines “good old fashioned efficacious” antibody technology with novel biology.

SciRhom:

SciRhom submits clinical trial application for first-in-human trials with lead candidate SR-878

The company’s lead candidate is an antibody designed to target a master switch for various autoimmune diseases, including rheumatoid arthritis (RA) and inflammatory bowel disease (IBD).

BIO-Europe 2023:

Presentation of IZB’s innovation powerhouse in the context of BIO-Europe 2023

Participants experienced the impressive density of research institutions and companies at this Munich life science hub.

GoingPublic:

GoingPublic celebrates a quarter century of biotech

At the Finance Day marking the anniversary, over 100 experts met at the IZB for exciting presentations, lively discussions and birthday cake for all.

Peutinger Collegium:

Renowned Peutinger-Collegium visits the IZB

The evening event focused on the achievements of the IZB and the issue of antibiotic resistance.

IZBrunch Nov 2023:

Dr. Andrea Schmidts, TUM and Dr. Patrick Großmann, CEO Invitris

The successful scientists presented new approaches to combat resistance to CAR-T cell therapy and the power of cell-free synthesis

Watch video

INTERN

Susanne Simon, Leitung Presse- und Öffentlichkeitsarbeit

IZB:

Susanne Simon leaves the IZB

She will join the ICPO Foundation as Head of Communications and Community of the ICPO Foundation (www.icpo.foundation) on 01.12.23.

"It has been an exciting 11 years at the IZB. Thank you very much for the wonderful collaboration," says Simon about her time at the IZB. Stay connected!

Contact

Marion Köhler
Head of Public Relation
Phone: 089/55 279 48-17
Mail: koehler@izb-online.de

Location Martinsried:

Fördergesellschaft IZB mbH
Am Klopferspitz 19
82152 Planegg/Martinsried

Location Weihenstephan:

Fördergesellschaft IZB mbH
Lise-Meitner-Straße 30
85354 Freising/Weihenstephan

What´s up at IZB

IZB News

IZB:

Christmas Greetings

IZB:

New image film of the IZB

EpiQmax:

MoleQlar receives seed funding from Rheingau Founders and acquires Munich-based epigenetics specialist EpiQMAxNOVEMBER 9, 2023

CatalYm:

Neutralizing GDF-15: Development of a new class of anti-cancer immunotherapy

SciRhom:

SciRhom submits clinical trial application for first-in-human trials with lead candidate SR-878

EVENTS

BIO-Europe 2023:

Presentation of IZB’s innovation powerhouse in the context of BIO-Europe 2023

GoingPublic:

GoingPublic celebrates a quarter century of biotech

Peutinger Collegium:

Renowned Peutinger-Collegium visits the IZB

IZBrunch Nov 2023:

Dr. Andrea Schmidts, TUM and Dr. Patrick Großmann, CEO Invitris

INTERN

IZB:

Susanne Simon leaves the IZB

Contact

Location Martinsried:

Location Weihenstephan:

MoleQlar receives seed funding from Rheingau Founders and acquires Munich-based epigenetics specialist EpiQMAx
NOVEMBER 9, 2023